Earnings ·
Liquidia reports Q3 net loss of $236.3M including $389.7M litigation settlement charge
LQDALiquidia Corp
Liquidia Corporation reported a third-quarter 2026 net loss of $236.3 million, or $2.64 per share, driven by a $389.7 million non-cash and cash charge for a global settlement resolving all pending litigation with United Therapeutics. Excluding the settlement impact, the company posted a GAAP net loss of $153.4 million but achieved fifth consecutive quarter of growth in non-GAAP adjusted EBITDA to $140.5 million. Net product sales for YUTREPIA reached $222.7 million, up 31% from the prior quarter, while cash and cash equivalents totaled $396.1 million before settlement payments. The company also announced Fast Track designation for YUTREPIA in SSc-RP and initiated a Phase 2 study for the indication. Liquidia Corporation is a biopharmaceutical company developing and commercializing products for respiratory and vascular diseases using its proprietary PRINT technology.